KLOW vs Wolverine: What the Research Shows
KLOW and Wolverine side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider KLOW if…
- you want the added KPV component, but note its evidence is mouse and cell work only (no human trial found): KPV-treated mice recovered earlier and regained more body weight in DSS colitis.[14]
Consider Wolverine if…
- you are weighing animal data: in a rat Achilles tendon study, combining BPC-157 and TB-500 gave no added benefit over either alone[15]
What they have in common
Spec comparison
Showing 4 of 12 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, WADA, Anti-doping detection, Half-life, Evidence strength, Typical study doses are the same or both unknown.
| Field | KLOW | Wolverine |
|---|---|---|
| Class | Four-peptide blend | BPC-157 + TB-500 blend |
| Also called | — | Wolverine stack, BPC-157 + TB-500 |
| Category | Healing & recovery | Healing & recovery |
| FDA status | Not FDA approved · unstudied blend | Not FDA approved · unstudied blend |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is. | Prohibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is. |
| Anti-doping detection |
|
|
| Half-life | BPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 | BPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 |
| Evidence strength | Human RCT evidence, 4 of 4TB-500: Cardiovascular research 2025, PMID 41229390 | Human RCT evidence, 4 of 4TB-500: Cardiovascular research 2025, PMID 41229390 |
| Human studies we summarised | 15 human (9 randomized or controlled) of 65 summarised, across ingredients | 10 human (7 randomized or controlled) of 41 summarised, across ingredients |
| Typical study doses |
|
|
| Vial sizes sold | 80 mg | 10 mg, 20 mg |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
A two-peptide stack against a four-peptide blend
A rat study tested BPC-157 and TB-500 separately and together: combined treatment did not confer additional benefits compared with either agent alone.[15]
In that rat study, maximum load to failure was higher in the BPC-157 and TB-500 groups than in controls, reaching statistical significance in the TB-500 group (p < 0.05).[15]
In a knee-pain survey, 14 of 16 patients (87.5%) had relief when BPC 157 or a combination of BPC 157 and TB4 was used.[16]
For GHK-Cu, a component KLOW adds, a diabetic neuropathic ulcer trial of a topical gel reported 98.5% median area closure against 60.8% for vehicle.[17]
The sports-medicine systematic review of BPC-157 says no clinical safety data were found.[18]
Regulatory and testing differences
BPC-157, a component of both products, is named on WADA's prohibited list.[1]
FDA's compounding review says it lacks sufficient information to know whether BPC-157 would cause harm when administered to humans.[19]
For KLOW's KPV component, FDA says it lacks important information on safety issues, including whether it would cause harm if administered to humans.[19]
BPC-157's elimination half-life was under 30 min in rats and beagle dogs.[6]
Common questions
Is KLOW better than the Wolverine stack?
No study in the cached results compares them. The rat experiment with BPC-157 plus TB-500 found no additional benefit over either agent alone.[15]
What does the Wolverine stack have that KLOW doesn't, and vice versa?
Wolverine is the BPC-157 and TB-500 pair; KLOW has those two plus GHK-Cu and KPV, the latter with no human exposure data according to FDA.[19]
Are KLOW and the Wolverine stack safe?
A BPC-157 intravenous infusion pilot reported that it was tolerated, with no side effects reported.[20]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 3Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 4Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
- 5Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 6Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 7Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
- 8A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
- 9Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
- 10Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 11PubMed search: (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab])) AND (("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12Drugs@FDA (openFDA) search: active ingredient "GHK-Cu"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 13Drugs@FDA (openFDA) search: active ingredient "BPC-157"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 14Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
- 15Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 16Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine · 2021PMID 34324435Accessed 2 Oct 2026
- 17Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 1994PMID 17147644Accessed 2 Oct 2026
- 18Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
- 19Official web pageOfficial web page · web page
- 20Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
Found an error? Report a correction.